Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas
Pier Luigi Zinzani, Vijayveer Bonthapally, Dirk Huebner, et al.
Critical Reviews in Oncology/Hematology (2016) Vol. 99, pp. 228-240
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

An overview of cutaneous T cell lymphomas
Nooshin Bagherani, Bruce R. Smoller
F1000Research (2016) Vol. 5, pp. 1882-1882
Open Access | Times Cited: 97
Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome
Louise Photiou, Carrie Van Der Weyden, Christopher McCormack, et al.
Current Oncology Reports (2018) Vol. 20, Iss. 4
Closed Access | Times Cited: 57
A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome
Walter Hanel, Robert Briski, Charles W. Ross, et al.
American Journal of Hematology (2016) Vol. 91, Iss. 12
Open Access | Times Cited: 47
Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth
Bo Ram Kim, Étienne Coyaud, Estelle Laurent, et al.
Molecular & Cellular Proteomics (2017) Vol. 16, Iss. 10, pp. 1864-1888
Open Access | Times Cited: 44
Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study
Anna Sureda, Ramón García‐Sánz, Eva Domingo‐Domènech, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1137-1137
Open Access
Genetics Abnormalities with Clinical Impact in Primary Cutaneous Lymphomas
Fernando Gallardo, Ramón M. Pujol
Cancers (2022) Vol. 14, Iss. 20, pp. 4972-4972
Open Access | Times Cited: 14
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States
Stefan K. Barta, Nicholas Liu, Maral DerSarkissian, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 24, Iss. 2, pp. e21-e32.e4
Open Access | Times Cited: 7
The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets
Jin-shu Pang, Zhe‐Kun Li, Peng Lin, et al.
Oncology Reports (2019)
Open Access | Times Cited: 19
Cutaneous T Cell Lymphoma
Erik Peterson, Jason Weed, Kristen Lo Sicco, et al.
Dermatologic Clinics (2019) Vol. 37, Iss. 4, pp. 455-469
Closed Access | Times Cited: 19
Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma
Fernando Gallardo, Joan Bertran, Erika López‐Arribillaga, et al.
Leukemia (2018) Vol. 32, Iss. 10, pp. 2211-2223
Open Access | Times Cited: 18
Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries
Chalid Assaf, Nathalie Waser, M. Bagot, et al.
Cancers (2021) Vol. 14, Iss. 1, pp. 145-145
Open Access | Times Cited: 14
Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents
Eytan M. Stein, Katharine Yen
Annual Review of Cancer Biology (2017) Vol. 1, Iss. 1, pp. 379-401
Open Access | Times Cited: 16
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?
Pooja Virmani, Susan Hwang, Justin G. Hastings, et al.
Expert Review of Hematology (2016) Vol. 10, Iss. 2, pp. 111-121
Closed Access | Times Cited: 14
The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review
Mehul Dalal, Stephen Mitchell, Conor McCloskey, et al.
Expert Review of Hematology (2020) Vol. 13, Iss. 4, pp. 405-419
Open Access | Times Cited: 11
Effects of 9-cis-retinoic acid on the proliferation and apoptosis of cutaneous T-cell lymphoma cells
Hua Yang, Yue Tao, Mengli Zhang, et al.
Anti-Cancer Drugs (2018) Vol. 30, Iss. 1, pp. 56-64
Closed Access | Times Cited: 11
Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines
Sara Pedretti, Mauro Urpis, C Leali, et al.
Tumori Journal (2017) Vol. 104, Iss. 5, pp. 394-400
Closed Access | Times Cited: 7
Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma
Ping Zhang, Mingzhi Zhang
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 7
Monoclonal antibodies against cutaneous T-cell lymphomas
Mauro Alaibac
Expert Opinion on Biological Therapy (2017) Vol. 17, Iss. 12, pp. 1503-1510
Closed Access | Times Cited: 6
Management of cutaneous T‐cell lymphomas: Established and emergent therapies
Thevaki Wain, Victoria L Venning, Germana Consuegra, et al.
Australasian Journal of Dermatology (2019) Vol. 60, Iss. 3, pp. 200-208
Closed Access | Times Cited: 6
Primary cutaneous peripheral T‐cell lymphoma not otherwise specified a rare and aggressive lymphoma
Alessandro Pileri, Claudio Agostinelli, Fabio Fuligni, et al.
Journal of the European Academy of Dermatology and Venereology (2018) Vol. 32, Iss. 10
Closed Access | Times Cited: 5
Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group
Mizuki Watanabe, Junya Kanda, Yasuyuki Arai, et al.
Biology of Blood and Marrow Transplantation (2020) Vol. 26, Iss. 12, pp. 2346-2358
Closed Access | Times Cited: 4
Hyperactive PLCG1 drives non-canonical signaling to promote cell survival
Longhui Zeng, Xinyan Zhang, Yiwei Xiong, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Treatments Relevant to Individual Cancer Types

(2024), pp. 359-410
Closed Access
Complete remission of aggressive T-cell LGL leukemia with pentostatin therapy: first case report
Margaret Li Krackeler, Catherine M. Broome, Catherine Lai
Stem Cell Investigation (2020) Vol. 7, pp. 24-24
Open Access | Times Cited: 3
Micellar Curcumin Substantially Increases the Antineoplastic Activity of the Alkylphosphocholine Erufosine against TWIST1 Positive Cutaneous T Cell Lymphoma Cell Lines
Antonios Trochopoulos, Yana Ilieva, Alexander Dimitrov Kroumov, et al.
Pharmaceutics (2022) Vol. 14, Iss. 12, pp. 2688-2688
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top